Exscientia’s $225 Million Series D Funding Round

Exscientia's $225 Million Series D Funding Round

Cooley LLP advised Exscientia on the deal.

Exscientia, a clinical-stage pharmatech company, announced its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion.

The Series D round also included participation from Novo Holdings, funds managed by BlackRock, Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol Myers Squibb. Exscientia, which uses artificial intelligence to design patient-based drugs, will leverage the new capital to advance its proprietary pipeline through clinical testing and continue expanding its technology platform toward autonomous drug design.

Exscientia is committed to discovering and designing the best possible medicines in the fastest and most effective manner. The company is the first to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created.

The Cooley team was led by Claire Keast-Butler (Picture) and Tom Goodman. It also included Charlotte Irvine, Paula Holland and Marc Recht. 

Involved fees earner: Tom Goodman – Cooley LLP; Paula Holland – Cooley LLP; Charlotte Irvine – Cooley LLP; Claire Keast-Butler – Cooley LLP; Marc Recht – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Exscientia;

Author: Federica Tiefenthaler